MBX insider buying – MBX Biosciences, Inc.
10 insider purchases since 2016 worth $45.7M by 8 different insiders. Last 12 months: 1 purchases, $525,585. Most recent filing: 2026-03-16.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| GORDON CARL L Director | $12.0M 1× · 750,000 sh | 2024-09-16 2024-09-16 | – | 747,887 shares as of 2025-02-19 | Holds - never sold |
| FHMLS X, L.P. Director | $12.0M 1× · 666,666 sh | 2025-09-26 2025-09-26 | – | 5,219,440 shares as of 2025-09-30 | Holds - never sold |
| Heron Patrick J Director | $10.0M 1× · 625,000 sh | 2024-09-16 2024-09-16 | – | 3,927,774 shares as of 2024-09-17 | Holds - never sold |
| NEA Partners 17, L.P. 10% Owner | $8.0M 1× · 500,000 sh | 2024-09-16 2024-09-16 | – | 1,023,103 shares as of 2024-09-17 | Holds - never sold |
| OrbiMed Genesis GP LLC Director | $2.0M 1× · 190,672 sh | 2025-02-14 2025-02-14 | – | 3,205,930 shares as of 2025-02-19 | Holds - never sold |
| Hawryluk P. Kent CEO | $1.3M 3× · 88,500 sh | 2025-02-04 2026-03-13 | – | 1,214,444 shares as of 2026-05-08 | Holds - never sold |
| Hoerter Steven L. Director | $265,000 1× · 20,000 sh | 2025-10-17 2025-10-17 | – | 102,938 shares as of 2026-08-04 | Holds - never sold |
| Pescovitz Ora H. Director | $45,312 1× · 7,693 sh | 2025-04-08 2025-04-08 | – | 24,329 shares as of 2026-06-05 | Holds - never sold |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 1 | $525,585 | 1 | 1 | $2.7M |
| 2025 | 6 | $15.1M | 5 | – | – |
| 2024 | 3 | $30.0M | 3 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2026-03-16 | Hawryluk P. Kent | CEO | 18,500 | $28.41 | $525,585 | +4.0% | SEC |
| 2025-10-21 | Hawryluk P. Kent | CEO | 20,000 | $13.64 | $272,800 | +4.5% | SEC |
| 2025-10-20 | Hoerter Steven L. | Director | 20,000 | $13.25 | $265,000 | SEC | |
| 2025-09-30 | FHMLS X, L.P. | Director | 666,666 | $18.00 | $12.0M | +14.6% | SEC |
| 2025-04-10 | Pescovitz Ora H. | Director | 7,693 | $5.89 | $45,312 | +46.2% | SEC |
| 2025-02-19 | OrbiMed Genesis GP LLC | Director | 190,672 | $10.60 | $2.0M | +6.2% | SEC |
| 2025-02-05 | Hawryluk P. Kent | CEO | 50,000 | $10.69 | $534,500 | +12.6% | SEC |
| 2024-09-17 | NEA Partners 17, L.P. | 10% Owner | 500,000 | $16.00 | $8.0M | +16.1% | SEC |
| 2024-09-17 | Heron Patrick J | Director | 625,000 | $16.00 | $10.0M | +15.9% | SEC |
| 2024-09-17 | GORDON CARL L | Director | 750,000 | $16.00 | $12.0M | +31.1% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Azoulay Salomon | Officer | 70,003 | $38.36 | $2.7M | Sale | SEC |
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free